Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FABP1 | P07148 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506305 | 0.85 | RAF1 (0.84) | RAF1TP53 | |
| SCHEMBL618034 | 0.84 | RAF1 (0.64) | RAF1KDR | |
| SCHEMBL1506293 | 0.82 | RAF1 (0.67) | RAF1TP53KDR | |
| SCHEMBL13852588 | 0.79 | RAF1 (0.52) | RAF1KDR | |
| SCHEMBL4248593 | 0.77 | RAF1 (1.00) | RAF1KDR | |
| SCHEMBL9945346 | 0.77 | KDR (0.73) | RAF1KDR | |
| SCHEMBL13855102 | 0.76 | RAF1 (0.67) | RAF1KDR | |
| SCHEMBL7654120 | 0.75 | RAF1 (0.63) | RAF1 | |
| SCHEMBL15612734 | 0.73 | RAF1 (0.70) | RAF1TP53KDR | |
| SCHEMBL617631 | 0.72 | RAF1 (0.65) | RAF1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | MAPK1, MAPK8, MAPK3 | RAF1 452/4885TP53 2392/4885KDR 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.